Daily Archives: May 28, 2022

Elevation Oncology Announces FDA Fast Track Designation Granted to Seribantumab for the Tumor-Agnostic Treatment of Solid Tumors Harboring NRG1 Gene…

Posted: May 28, 2022 at 8:19 pm

NEW YORK, May 25, 2022 /PRNewswire/ --Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to seribantumab for the tumor-agnostic treatment of advanced solid tumors that harbor NRG1 gene fusions. Seribantumab is currently being evaluated in the ongoing Phase 2 CRESTONE study, for which initial data will be presented in an oral presentation at the upcomingAmerican Society of Clinical Oncology (ASCO) 2022 Annual Meeting on Tuesday, June 7, 2022.

"There are currently no approved therapies that specifically target NRG1 fusions, and therefore, receipt of Fast Track designation in a tumor-agnostic setting is a significant step in addressing this unmet need," said Shawn M. Leland, PharmD, RPh, Founder and Chief Executive Officer of Elevation Oncology. "NRG1 fusions are a type of genomic alteration that causes unregulated cell growth and proliferation in a variety of solid tumors, and we look forward to working closely with the FDA as we continue exploring the potential of seribantumab to improve outcomes for patients whose tumor harbors this unique oncogenic driver."

Fast Track is an FDA process designed to facilitate the development and expedite the review of potential therapies that seek to treat serious conditions and fill an unmet medical need. A drug candidate that receives Fast Track designation is afforded greater access to the FDA for the purpose of expediting the drug's development, review and potential approval. Additionally, the designation allows for eligibility for Accelerated Approval and Priority Review, if relevant criteria are met, as well as a Rolling Review, which means a drug company can submit completed sections of its New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be submitted for review.

About Seribantumab and NRG1 Gene Fusions

Seribantumab is a fully human IgG2 monoclonal antibody that binds to human epidermal growth factor receptor 3 (HER3). HER3 is traditionally activated through binding of its primary ligand, neuregulin-1 (NRG1). The NRG1 gene fusion is a rare genomic alteration that combines NRG1 with another partner protein to create chimeric NRG1 "fusion proteins". The NRG1 fusion protein is often also able to activate the HER3 pathway, leading to unregulated cell growth and proliferation. Importantly, NRG1 gene fusions are predominantly mutually exclusive with other known genomic driver mutations and are considered a unique oncogenic driver event associated with tumor cell survival.

NRG1 fusions have been identified in a variety of solid tumors, including lung, pancreatic, gallbladder, breast, ovarian, colorectal, neuroendocrine, cholangiocarcinomas, and sarcomas. In preclinical experiments, seribantumab prevented the activation of HER3 signaling in cells that harbor an NRG1 gene fusion and destabilized the entire ERBB family signaling pathway including the activation of HER2, EGFR, and HER4. In addition to extensive nonclinical characterization and testing, seribantumab has been administered to over 800 patients across twelve Phase 1 and 2 studies, both as a monotherapy and in combination with various anti-cancer therapies. Seribantumab was granted Fast Track designation from the FDA for the tumor-agnostic treatment of patients whose solid tumors harbor NRG1 fusions and is currently being evaluated in the Phase 2 CRESTONE study for patients with solid tumors of any origin that have an NRG1 fusion.

About the Phase 2 CRESTONE Study

CRESTONE (Clinical Study of Response to Seribantumab in Tumors with Neuregulin-1 (NRG1) Fusions; NCT04383210) is a Phase 2 tumor-agnostic study evaluating seribantumab in patients with solid tumors that harbor an NRG1 fusion and have progressed after at least one prior line of standard therapy. The primary objective of the study is to describe the anti-tumor activity and safety of seribantumab as a monotherapy specifically in patients whose solid tumor is uniquely driven by an NRG1 gene fusion. CRESTONE offers a clinical trial opportunity for patients with advanced solid tumors who have not responded or are no longer responding to treatment. Patients are encouraged to talk to their doctor about genomic testing of their tumor. CRESTONE is open and enrolling today in the United States, Australia, and Canada. For more information visit http://www.NRG1fusion.com.

About Elevation Oncology, Inc.

Elevation Oncology is founded on the belief that every patient living with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. We aim to make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of tumor growth. Together with our peers, we work towards a future in which each tumor's unique genomic test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Our lead candidate, seribantumab, is intended to inhibit tumor growth driven by NRG1 fusions and is currently being evaluated in the Phase 2 CRESTONE study for patients with solid tumors of any origin that have an NRG1 gene fusion. Details on CRESTONE are available at http://www.NRG1fusion.com. For more information visit http://www.ElevationOncology.com.

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development activities, expected timing of announcements of clinical results, potential benefits of seribantumaband the company's other future product candidates, potential opportunities to expand the company's product candidate pipeline, potential market opportunities for seribantumaband the company's other future product candidates, the ability of seribantumaband the company's other future product candidates to treat their targeted indications, and our expectations about our cash runway. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "might," "plan," "potential," "possible," "will," "would," and other words and terms of similar meaning. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, the company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company's ability to advance its product candidates, the timing and results of preclinical studies and clinical trials, approvals and commercialization of product candidates, the receipt and timing of potential regulatory designations, the impact of the COVID-19 pandemic on the Company's business, the Company's ability to fund development activities and achieve development goals, the Company's ability to protect intellectual property, the Company's ability to establish and maintain collaborations with third parties and other risks and uncertainties described under the heading "Risk Factors" in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Elevation Oncology Investor and Media ContactCandice Masse, 978-879-7273Senior Director, Corporate Communications & Investor Relations[emailprotected]

SOURCE Elevation Oncology

More here:
Elevation Oncology Announces FDA Fast Track Designation Granted to Seribantumab for the Tumor-Agnostic Treatment of Solid Tumors Harboring NRG1 Gene...

Posted in Gene Medicine | Comments Off on Elevation Oncology Announces FDA Fast Track Designation Granted to Seribantumab for the Tumor-Agnostic Treatment of Solid Tumors Harboring NRG1 Gene…

INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual…

Posted: at 8:19 pm

INOVIO's DNA medicines immunotherapy in combination with Libtayo elicits vaccine-associated immune responses when administered with RT/TMZ to newly diagnosed GBM patients

INO-5401 + INO-9012 + Libtayoelicits cancer antigen-specific T cells

55% of MGMT methylated subjects remain alive at a median of 32.5 months

Dr. David Reardon, Principal Investigator, to present on June 6, 2022 at ASCO

PLYMOUTH MEETING, Pa., May 27, 2022 /PRNewswire/ -- Inovio (NASDAQ: INO) announced results from the company's novel Phase 1/2 trial of INO-5401 and INO-9012 in combination with PD-1 inhibitor Libtayo (cemiplimab) in the treatment of newly diagnosed glioblastoma (GBM), including encouraging median overall survival (OS) data from fifty-two subjects. Median OS duration in unmethylated MGMT (Cohort A) was 17.9 months. Median OS data in MGMT Methylated patients (Cohort B) are being presented for the first time, at a median of 32.5 months, which compares favorably to historical comparisons (23.2-25 months).

Overall, INO-5401 + INO-9012 is demonstrated to be tolerable and immunogenic when administered with Libtayo and RT/TMZ (radiation and temozolomide) to newly diagnosed GBM patients. Notably, INO-5401 elicited antigen-specific T cells that may infiltrate GBM tumors. The data from this study was selected to be presented in an oral presentation by Dr. David Reardon on Monday, June 6, 2022, at the 2022 American Society of Clinical Oncology (ASCO) at the McCormick Place Convention Center in Chicago, Illinois.

Presentation Details: June 6, 2022, 12:42 12:54 p.m. CDTPresenting Author: David A. ReardonCentral Nervous System Tumors Session

Abstract #2004: Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma

Fifty-two subjects were enrolled: 32 in Cohort A; 20 in Cohort B (35% women; median age 60 years [range 19-78 years]). The adverse event profile was consistent with known single-agent (INO-5401, INO-9012, EP or Libtayo) events; most events were Grade 2 and no related events were Grade 4. Median OS durations in Cohorts A and B were 17.9 months (95% CI 14.5-19.8) and 32.5 months (95% CI 18.4-not reached), respectively. Flow cytometry revealed activated, antigen specific CD4+CD69+PD1+ and CD8+CD69+PD1+ T cells, the latter with lytic potential as defined by presence of perforin and granzyme A. Both subsets exhibited HR<1.0 and p<0.05 when accounting for a 0.1% T cell frequency change, translating to a 23% and 28% reduced risk of death at 18 months, respectively.

A post-hoc exploratory analysis showed that gene expression levels of INO-5401 antigens and immune cell markers from pre-treatment tumor tissues were similar between alive and deceased groups; however, the alive group displayed significant differential expression of genes regulating apoptosis, proliferation, and immune responses. Post-treatment tumor tissue displayed altered gene expression for immune-related markers versus pre-treatment tissue, including markers of T cell infiltration, activation, and lytic potential.

Dr. David Reardon, Clinical Director, Center for Neuro-Oncology of Dana-Farber Cancer Institute and coordinating principal investigator of the study said, "GBM remains one of the most aggressive and hard-to-treat cancers. The fact that we have seen this novel combination trial of a T cell generating DNA medicine combined with a PD-1 checkpoint benefit a large percent of trial participants past 32 months is very encouraging. These latest results and continued development are welcoming as it continues to improve upon a standard of care which was defined 17 years ago and remains sub-optimal for our patients with GBM."

Dr. Jeffrey Skolnik, INOVIO's Senior Vice President, Clinical Development, said, "We, along with our collaborative partner Regeneron, remain encouraged with the progress to date from this novel combination therapy study. As concluded in the abstract, INO-5401 + INO-9012 has an acceptable risk/benefit profile and elicits robust immune responses that may correlate with a potentially enhanced survival when administered with Libtayo and RT/TMZ to newly diagnosed GBM patients. Our goal is to build upon INO-5401's ability to elicit antigen-specific T cells that can infiltrate GBM tumors and complement the clinically-active profile of Libtayo to a potentially larger study in the future."

INO-5401, INO-9012, Libtayo, and the combination of these products have not been approved or evaluated by any Regulatory Authority worldwide for the treatment of newly diagnosed GBM.

Study Design

The trial was designed to evaluate safety, immunogenicity and efficacy of INO-5401 and INO-9012 in combination with Libtayo, with radiation and chemotherapy, in subjects with newly diagnosed glioblastoma (GBM). This is a Phase 1/2, open-label, multi-center trial conducted in 52 evaluable patients with GBM. There are two cohorts in this trial. Cohort A includes 32 participants with a tumor with an unmethylated O6-methylguanine-deoxyribonucleic acid (DNA) methyltransferase (MGMT) promoter. Cohort B includes 20 participants with a tumor with a MGMT methylated promoter. Both cohorts received INO-5401 and INO-9012 and Libtayo at the same doses and on the same dosing schedule, and both cohorts received radiation and TMZ. For more information of the clinical study, see http://www.clinicaltrials.gov, identifier NCT03491683.

About INO-5401 and INO-9012

INO-5401 encodes for INOVIO's SynCon antigens for hTERT, WT1, and PSMA, and has the potential to be a powerful cancer immunotherapy in combination with checkpoint inhibitors. The National Cancer Institute previously highlighted hTERT, WT1, and PSMA among a list of important cancer antigens, designating them as high priorities for cancer immunotherapy development. These three antigens were reported to be over-expressed, and often mutated, in a variety of human cancers including glioblastoma, and targeting these antigens may prove efficacious in the treatment of patients with cancer. INO-9012 encodes for IL-12, which is a T cell immune activator.

About Glioblastoma (GBM)

GBM is the most common and aggressive type of brain cancer and remains a devastating disease for both patients and caregivers. Its prognosis is extremely poor, with very few new therapies approved over the last 10 years. The median overall survival for patients receiving standard of care therapy is approximately 15 to 22 months and the median progression-free survival is approximately 7-10 months. In the U.S., the estimated annual incidence of GBM is 11,362 cases or 3.21 cases per 100,000 persons and the median age at diagnosis is 65 years.

About INOVIOINOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases. Our DNA medicines are delivered using our proprietary smart device to produce a robust and tolerable immune response against targeted pathogens and cancers.

Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense/Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. For more information, visit http://www.inovio.com.

CONTACTS:

Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.comInvestors: Ben Matone, 484-362-0076, ben.matone@inovio.com

This press release contains certain forward-looking statements relating to our business, including our plans to develop DNA medicines, our expectations regarding our research and development programs, including the planned initiation and conduct of preclinical studies and clinical trials and the availability and timing of data from those studies and trials, and our ability to successfully manufacture and produce large quantities of our product candidates if they receive regulatory approval. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, our ability to secure sufficient manufacturing capacity to mass produce our product candidates, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2021, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.

View original content:https://www.prnewswire.com/news-releases/inovio-announces-survival-results-for-ino-5401--ino-9012-in-combination-with-libtayo-cemiplimab-in-patients-with-newly-diagnosed-gbm-at-asco-annual-meeting-2022-301556446.html

SOURCE INOVIO Pharmaceuticals, Inc.

More:
INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual...

Posted in Gene Medicine | Comments Off on INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual…

Outlook on the Single-use Technologies for Biopharmaceuticals Global Market to 2026 – Increasing Demand for Personalized Medicine is Driving Growth -…

Posted: at 8:19 pm

DUBLIN, May 27, 2022 /PRNewswire/ -- The "Single-use Technologies for Biopharmaceuticals: Global Markets" report has been added to ResearchAndMarkets.com's offering.

The report summarizes the market, including a market snapshot and company profiles of key players in the sole-use technologies market. It provides a comprehensive market breakdown with in-depth information about each segment. The overview section of the report describes market trends and dynamics, including drivers, limitations, challenges, and opportunities for the market.

Furthermore, it provides information about market development and future trends useful for organizations, including distributors and exporters. It analyzes critical market players' revenue, product portfolio and recent activities. It further includes strategies adopted by emerging market players with strategic recommendations for new market entrants. Outright information is provided in the report, consisting of historical and current market size, including the market's future potential.

The report will also help inform market players and new entrants about the production and export of goods and services to original equipment manufacturers. The market is segmented based on technology, components, applications, and end user. A geographical market analysis is provided for all the major segments. The report offers a country-level analysis of the market to understand major components better.

Report Includes

Single-use bioreactor technology has gained considerable importance in biotechnology manufacturing over the years. Several single-use options are available. Scalability is the biggest limitation. The industry's willingness to use single-use bioreactors is influenced by production parameters, product value and development time. It takes more time to complete comparative studies with conventional stainless-steel bioreactors as the rate of implementation is lower than that of acceptance, thus making single-use technology highly desirable in the biopharmaceutical industry.

However, more clarity and understanding regarding the regulatory requirements for single-use bioreactor technology are needed. For example, U. S. FDA regulations for the Cord Blood Registry (CBR) do not explicitly mention single-use bioreactor technology, even though a large number of Investigational New Drug (IND) programs have been approved by the FDA using such systems.

The major factors influencing the growth of the market include increasing demand for personalized medicine, extensive ongoing development efforts, a strong product portfolio, and large application areas for single-use systems. Additionally, lower cost and reduction in the time necessary in the biomanufacturing process when using single-use technology are further driving the growth of the market.

The drug development rate has increased rapidly with the increasing demand for personalized medicines. This has, in turn, increased the demand for single-use technology to avoid the risk of contamination.

A strong product portfolio is further fueling the growth of the market during the forecast period. There are several companies that are offering single-use technologies, such as Thermo Fisher Scientific Inc. , Danaher Corp. , Sartorius AG, General Electric Co. , and PendoTECH LLC. PendoTECH LLC is focused on the development of pressure sensors used to measure static and dynamic pressure of gases and liquids in biopharmaceutical processes.

It also provides a wide range of single-use products such as single-use rotary flowmeters, single-use ultrasonic flowmeters and a compact low-flow ultrasonic flow meter with are usable fluid path.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 Biologics Process Development Pathway and Application of Single-Use Technologies

Chapter 5 Covid-19 Impact on Market

Chapter 6 Market Breakdown by Technology

Chapter 7 Market Breakdown by Single-Use Component

Chapter 8 Market Breakdown by Application

Chapter 9 Market Breakdown by End-user

Chapter 10 Market Breakdown by Region

Chapter 11 Patent Review

Chapter 12 Competitive Analysis and Market Opportunities

Chapter 13 Company Profiles

Chapter 14 Appendix: Abbreviations

For more information about this report visit https://www.researchandmarkets.com/r/xzilpr

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

See the article here:
Outlook on the Single-use Technologies for Biopharmaceuticals Global Market to 2026 - Increasing Demand for Personalized Medicine is Driving Growth -...

Posted in Gene Medicine | Comments Off on Outlook on the Single-use Technologies for Biopharmaceuticals Global Market to 2026 – Increasing Demand for Personalized Medicine is Driving Growth -…

Losing Ourselves: Learning to Live Without a Self – Next Big Idea Club Magazine

Posted: at 8:19 pm

Jay L. Garfield is the Doris Silbert Professor in the Humanities and Professor of Philosophy, Logic, and Buddhist Studies at Smith College and a visiting professor of Buddhist philosophy at Harvard Divinity School.

Below, Jay shares 5 key insights from his new book, Losing Ourselves: Learning to Live Without a Self. Listen to the audio versionread by Jay himselfin the Next Big Idea App.

Id like to begin with a little story from the 7th-century Indian philosopher, Chandrakirti. He tells the story of a man who is worried that a snake has taken up residence in the wall of his house. If you live in India, this is pretty dangerous because a lot of the snakes are poisonous. The man looks through the house, reassures himself that theres no elephant there, and then he relaxes. Chandrakirti says, What an idiot that guy is!

Whats the point of the story? The snake is our self, and we often are convinced that that particular snake has taken up residence in our own homesthat we are ourselves. When we try to really figure out who we are, we might reject the idea that Im a body, that Im a mind, and so forth, but still that self, that snake, remains there.

Its important to begin by identifying that delusion so that we can see how dangerous it is. I like to do that using a thought experiment: We could begin by imagining somebody else whose body wed really like to have. I, for example, would like to have Usain Bolts body from a few years ago, just for about 9.4 seconds, because Id love to know what it feels like to run that fast. The moment I form that desire, Im telling myself that I do not identify my self with my body, because I think of myself as somebody who has a body, and who could have another body; I think of myself as the thing that owns my body. We can do the same thing with our mindsId really like to have Stephen Hawkings mind when he was at his peak, because Id love to be able to understand general relativity, gravitation, and all of that cool stuff.

The very fact that I can imagine that desirenot wanting to be Stephen Hawking or to be Usain Bolt, but to have their mind and body respectivelytells me that I dont, deep down, think of myself as identical to my mind, but rather as the guy who has my mind, and could have had a better one. Its that thing, the self, that stands behind mind and bodythat has the mind, that has the bodythats the target.

I think that that self has got to be an illusion. In fact, I think its a stupid idea, because after all, when you take your body and mind away and you ask whats left, theres nothing really there. Its the idea of something that stands outside of the worldthe pure subject that experiences the world and acts on the world, but is not in the world.

The 20th-century Austrian philosopher Ludwig Wittgenstein described that as thinking of ourselves as like the eye in the visual fieldnot in the field, but standing behind it. Similarly, when we think of ourselves as selves, we take ourselves out of the world. But we know that were just biological organisms in the world, so we know that thats an illusion, even if its an illusion that evolution has wired us for.

A great way to get a handle on the difference between these two views is to think about the etymology of the word person in English. It comes from the word persona, which refers to a maskand in particular, the mask that an actor would wear in the classical theater. Persona became a word for a role in the theater, and we still have that in the phrase dramatis personae when we look at a play. The personae are the roles, not the actors. Similarly, we can think of ourselves not as actors, but as roles.

Think, for instance, about the difference between the role of Hamlet and the many actors who have played HamletSir Laurence Olivier, Benedict Cumberbatch, and so forth. The fact that Benedict Cumberbatch played Hamlet does not make Hamlet a contemporary Englishman, nor does it make Benedict Cumberbatch a fictional character. It means that the role of Hamlet survives different particular players; its constituted by a story, by a fiction, by the conventions of the theater, by being played by many people.

Thats how we are. We are constituted by the social practices in which we engage, by the families in which were raised, and by the cultures in which we live. Just as Hamlet changes from Sir Laurence Olivier to Benedict Cumberbatch, we constantly change as we get older, as we learn, and as we engage in social interaction with others.

This is really cool, because it means that were not imprisoned as static, permanent selves that stand behind the world; we are beings in constant, open engagement with others. This facilitates a kind of spontaneity and better ethical engagement.

One of the dangerous things about the self illusion is that it leads us to thematize our experience in terms of subject-object duality. We think of ourselves as pure subjects and everything else as objects, and that really distorts life because it takes the entire world as existing as our object, and us as outside of the world. It forgets that we are actually part of the world; it forgets that when I perceive the world, I only do so through the world entering me through my sensory apparatus, through my cognition, and through my experience. In fact, Im always part of the world, non-dually related to it, even though Im constantly maybe superimposing a duality.

The interesting point is that we dont always superimpose subject-object duality, or thematize ourselves as transcendent subjects; there are times when we forget ourselves completely. Psychologists call these flow states, states when we simply forget ourselves in seamless, effortless engagement with the world. We find this in really expert performancein great athletic performance, in musical performance, in dance, even when were engaged in a really great conversation with a friend, or observing objects of art, or lost in the contemplation of nature. We dont really notice ourselves, and dont thematize that duality.

Flow is a sign of expertiseit shows us that were able to do something spontaneously and without effort. When were in flow, we perform at our best and were happier, and it distinguishes a beginner or amateur from expert performance.

Theres a neat way to see this. If you think about the reasons for attending to ourselves and thematizing our experience in subject-object duality, that often works best when were acquiring a skill. If youre teaching somebody to play a musical instrument or play a sport, you ask them to direct their attention to their bodies, to what theyre doing, and to their interaction with whats around them. You stimulate subject-object duality, and that helps people get better.

But it turns out that if you ask experts to attend to themselves, to attend to their bodies, to pay attention to what theyre doing, that degrades their performance. That teaches us that subject-object duality is useful for learning, but we want to shed it when we get to expertise. Thats why I think that because the self underlies this idea of subject-object duality, in order to become really expert people, to lead virtuoso lives, we need to shed the self and recognize ourselves as personsbeings in constant, open, dynamic interaction with others and with our environment.

The moment we distinguish self from everything else, the moment we superimpose subject-object duality on all of our interactions, we set the stage for moral egoism. If we are the only subject and everything else is object, thats reason to take ourselves very, very seriously. It locates us at the center of our interactive social universe and at the center of our moral universe. It leads us to believe that we are somehow free from causality in that we simply act as independent, autonomous agents. It also leads us to treat others as though they are autonomous agents, and by doing that, we forget all the causal determinants of our behavior. We forget that what we do depends on what we believe, on what we intend, on what we see, and also on our emotional state and how were brought up.

Thats true of others around us, too. That can exaggerate our own sense of agency, leading to unjustified pride and egoism. It can also exaggerate our sense of others agency, leading us to blame people for things for which they really dont deserve blame. This makes us more reactive and less responsive. It makes it impossible to cultivate genuine human connections. If we understand ourselves as persons, as ensemble actors in the same big play as everybody else, then were able to interact with others in a more selfless way, a way characterized by care, friendliness, a commitment to relieve their difficulties, a commitment to help others become happier as we become happierwith sympathetic joy, with the ability to take pleasure not only in our own achievements, but also in the achievements of others.

When we do that, we de-center ourselves. We take ourselves out of the center of the moral universe and recognize that we are simply one actor among many in the grand cast of the human world. That allows us to who engage with others in a kinder, gentler, more open way, and gives us a much more realistic view of exactly who we are and who others are.

Ive been suggesting that were more like roles than we are like actorsthat is, that we are kind of fictional beings, made up. But the words fact and fiction, in English, are actually cognate. A fact is something thats madewe have the word factory, where we make thingsand a fiction is something thats been made up. These words in old English were very, very close, and theyve only diverged more recently.

The important point here is that fictions create facts. The fiction of Hamlet creates the fact that Hamlet was a prince of Denmark, and not Ophelia. It creates the fact that Hamlet dies in the last scene. It creates the fact that Rosencrantz and Guildenstern are Hamlets friends, and that fact leaks out of Shakespeares play and into Tom Stoppards.

Fictions do create facts. The grand fiction in which we participate creates the facts that we take most seriously in our lives. That also means that the fiction that we write is not a fiction that I author or that you author, but a fiction that all of us author togethera collectively authored improv fiction. Thats because we have evolved to be highly social beings, beings whose identity only emerges in interaction with others. We learn to be the social beings we are through our interactions with others, through the way our parents bring us up, through our childhood, and through our practice as adults. By understanding that we become who we are only among others, and that everybody with whom we interact has a hand in shaping us, just as we have a hand in shaping all of those with whom we interact, we can replace a sense of autonomy and isolation with a sense of fellowship and gratitude toward others.

To listen to the audio version read by author Jay Garfield, download the Next Big Idea App today:

See the article here:

Losing Ourselves: Learning to Live Without a Self - Next Big Idea Club Magazine

Posted in Ethical Egoism | Comments Off on Losing Ourselves: Learning to Live Without a Self – Next Big Idea Club Magazine

Altercation: The Best (Progressive) Democrat You Probably Never Heard Of – The American Prospect

Posted: at 8:18 pm

Eric Alterman is lecturing and traveling in Israel and Jordan this week, and so todays Altercation is authored by the historian Michael Kazin, a professor of history at Georgetown University and the author, most recently, of What It Took to Win: A History of the Democratic Party, from which the below is adapted.

To judge by media coverage of the Democrats, youd think nothing is going on within the party but battles between progressives who want to pass sweeping pieces of legislation like Build Back Better and the PRO Act and moderates who fret that increasing federal spending will add to inflation and alienate business. This may be unfairthe mainstream media often arebut we would be fooling ourselves were we to fail to admit that the party itself has a serious identity problem.

In fact, there are more influential progressives or leftists (or whatever your term of choice) inside the Democratic Party now than at any time in decades. To make a lasting difference in the life of the countryrather than winning Twitter fights or gaining face time on MSNBCthey might learn something from the career of a bygone senator from New York who may have been the most powerful progressive who never ran for the White House in the two centuries the Democrats have existed as a mass institution.

During that span, a remarkable array of heroes and villains have made the party their political home. The virtuous set obviously includes Franklin D. Roosevelt, who signed into law Social Security and other pillars of the limited welfare state, and led the nation to victory in World War II. It also includes John Lewis, who fought for voting rights for all Americans as a young activist and then spoke out for economic as well as racial equality during his 19 terms in Congress. Among the rogues are Roger Taney, a close aide to Andrew Jackson, who appointed him chief justice of the United States. From the bench in 1857, Taney intoned that Black people had no rights which the white man was bound to respect. And then there is George Wallace, the infamous Alabama governor, who exploited white hostility toward civil rights and liberal elites to become a darling of the far right in the 1960s and early 1970s.

But to name such figures, whether famous or infamous, neglects those party stalwarts, scarcely remembered today, who labored hard and long to enact critical reforms that stand as hallmarks of progressive achievement. Throughout their history, Democrats have done best when they espoused a vision of moral capitalism and policies to match. At a time when Democrats are struggling to enact programs like universal pre-kindergarten and expanded Medicare benefits, they can learn from the careers of once prominent, now little known, lawmakers who won election after election by championing policies to help the great majority of working Americans.

Most prominent among the forgotten is Robert Ferdinand Wagner. Born in a German Rhineland village in 1877, Wagner emigrated to New York City with his parents a few years later. His father had owned a small business in the Old Country but made his living as a janitor in the New World, at a salary of about a dollar a day. Discontented with his lot, Reinhard Wagner and his wife sailed back to Germany near the end of the 19th century and never returned. But Robert completed high school and then graduated from City College in Manhattan. He won an award as class orator that presaged his future career in politics.

Read more Altercation

Wagner soon enlisted in the ranks of Tammany Hall, the citys potent Democratic machine. In 1904, he got elected, with Tammanys endorsement, to the New York state legislature. With the help of female reformers like Frances Perkins (who later became labor secretary during the New Deal), he worked to pass bills for accident compensation and factory inspection aimed to prevent horrible events like the 1911 fire at the Triangle Shirtwaist Company that killed 146 workers, most of them female immigrants. Mary Dreier, a pioneer labor organizer, recalled traveling with Wagner to vegetable farms in upstate New York where young women toiled for as long as 19 hours a day. She recalled that Wagner was very astute asking questions about the children, who often accompanied their mothers to the fields.

In 1926, Wagner won a seat in the U.S. Senate by clinging to the coattails of Al Smith, then his states popular governor. On Capitol Hill, he proposed measures to aid the unemployed and use government funds to stabilize the economy. When FDR became president, Wagner seized a unique opportunity to pass bold initiatives to markedly improve the lives of working Americans. Leon Keyserling, a 27-year-old economist on his staff, wrote the National Labor Relations Act, which the press immediately dubbed the Wagner Act, although it was co-sponsored with a congressman from Massachusetts. The senator also introduced bills to erect millions of units of public housing and provide every citizen with health insurance. Wagners reputation as the most prominent and most effective labor liberal in America made him the natural choice to oversee the drafting of the 1936 Democratic platform, on which FDR ran his campaign for re-election that carried all but two states and gave the Democrats huge majorities in both houses.

Wagner was also one of the few Democrats in Congress whose empathy for ordinary people never faded at the color line. In 1934, he proposed a bill to make lynching a federal crime and fought, in vain, to stop Southerners in his party from filibustering it to death. He also sought to amend the Social Security Act and his own National Labor Relations Act to include domestic workers and farmworkersoccupations held by two-thirds of Black workers in the South. But the New Yorker and his fellow liberals lost that struggle, too; Southern Democrats composed too large a bloc in the party and had too much power in Congress. But Wagner did show his unflagging commitment to racial equality when he proposed, in 1940, a successful amendment to the new Selective Service Act that outlawed discrimination in the Army Air Corps and other elite branches of the military.

The German immigrant had come a long way from his days as a young cog of the New York Democratic machine. Still, Wagner understood just how essential both loyalty and a strong organization were in politicsand so he kept the faith. Tammany Hall may justly claim the title of the cradle of modern liberalism in America, he told an Independence Day crowd in 1937.

Wagner had another exemplary quality few politicians have ever possessed: He was as lacking in egotism and a hunger for adoration as any intensely public man could be. One New York journalist who followed Wagner throughout his career described him as an unassuming man sincere and unaffected, he has neither the desire nor the talent for self-exploitation. The senator, groused another reporter, does not put on a good show.

Yet in his modest fashion, he did as much as any New Dealer but FDR himself to advance, in the words of his partys 1940 platform (which Wagner drafted), the essential freedom, dignity and opportunity of the American worker. And he did this in a period of depression and foreign war that tested the survival of democracy in the nation and the world more than at any time in history.

Wagner remained in the Senate until near his death in 1953. A year later, his only child, Robert Wagner Jr., was elected mayor of New York City. The consistent labor liberal ran the metropolis until 1965. During his final term, he broke with Tammany Hall, whose clout had weakened considerably since it had launched his fathers eminent career.

If Democrats hope to dominate national politics again. as they did during the middle of the last century, they will have to develop leaders able to build a strong organization committed to advancing the economic interests of Americans who work hard but have too little to show for it. This is the hard, unglamorous work of politics. It requires both movement-building and deal-making, and if any current progressive Democrat wishes to earn him- or herself a record like that of Robert Wagner, they had better get to work on both.

Michael left us some room that should not go to waste, so here, from the Journal of the History of Ideas, is a forum on Black intellectual history that definitely will not make it into any of the curricula in Florida or Virginia anytime soon.

And I did not want to go two weeks in a row with no music. I am a fan of cover versions and I wrote up some of my favorite way back when The New York Times asked me to pick some in 2008, here. I am also a fan of Mr. Springsteen and so todays bonuses include Bruce doing Love Me Tender and Drift Away, Like a Rolling Stone, and the famous Leipzig 2013 You Never Can Tell, with over 60,000,000 views. Bruce apparently did not remember that he did the song (also unrehearsed) in 2009, but the bootleg I grew up listening to was from 1974. Listen to how differently Bruce used to talk on stage back then: Im married, Im selling insurance

And if you remember this song (and useful metaphor) fondly, as I do, then you ought to love this one perhaps even more.

See the original post here:

Altercation: The Best (Progressive) Democrat You Probably Never Heard Of - The American Prospect

Posted in Democrat | Comments Off on Altercation: The Best (Progressive) Democrat You Probably Never Heard Of – The American Prospect

How the Democrats Can Become the Party of the People Again – The New Republic

Posted: at 8:18 pm

In my view, these solidly red states provide fertile ground for populist Democratic challengers who are willing to run against the party establishment and in favor of strong working-class appeals. In 2020 in Kentucky, Charles Booker took on his own partys favored candidate, Amy McGrath, in the Senate primary and almost won. Today, due to his resilience, he is the partys nominee to take on Rand Paul in November.

Consider Alabama. A state that has witnessed two campaigns to unionize Amazon in the past couple of years and has seen a brutal union-busting effort by the Warrior Met Coal company against its own workers. These worker-led movements have popular support in the state. Alabamians are hungry for someone to speak to their pain, carry their fight in the political area, and importantly, take on a struggle that necessarily entails friction with their wealthy corporate paymasters. Due to GOP Senator Richard Shelbys retirement, there is an open seat. This should be fertile ground for redefinition of the Democratic brand. And while the contest might not be immediately successful, waging this kind of battle is necessary for repositioning the party to potentially win down-ballot seats or even claim a Senate victory in the years to come.

The alternative is to simply give up. But it wasnt that long ago when Democratsbuffeted by FDR/New Deal branding and the molding of generations of Democratic votersheld Senate seats in places like Alabama, Arkansas, Indiana, North Dakota, and Louisiana, all of which have races this year. Its just like Edison said: The most certain way to succeed is always to try just one more time.

Here is the original post:

How the Democrats Can Become the Party of the People Again - The New Republic

Posted in Democrat | Comments Off on How the Democrats Can Become the Party of the People Again – The New Republic

Will Texas pick a progressive or anti-abortion Democrat in heated runoff? – The Guardian US

Posted: at 8:18 pm

Two nearly identical text boxes appear on the respective campaign websites for Henry Cuellar and Jessica Cisneros, the Democrats locked in a heated primary runoff to represent south Texas in Congress.

Cuellars text box warns voters that Cisneros would defund the police and border patrol, which would make us less safe and wreck our local economy. Cisneros, in turn, blasts Cuellar for opposing womens right to choose amid a nationwide crackdown on reproductive care.

The parallel advisories read like shorthand for the battle thats brewing among Democrats in Texas, where centrist incumbents like Cuellar are facing a mushrooming cohort of young and progressive voters frustrated by the status quo.

I want people to take away from what were doing people-power people can go toe-to-toe with any kind of corporate special interest, Cisneros told the Guardian. And that we still have power over what we want our future and our narrative to be here in Texas, despite all odds.

Texas-28 is a heavily gerrymandered, predominantly Latino congressional district that rides the US-Mexico border, including the city of Laredo, before sprawling across south-central Texas to reach into San Antonio. During the primary election in March, voters there were so split that barely a thousand votes divided Cuellar from Cisneros, while neither candidate received the majority they needed to win.

Now, the runoff on 24 May has come to represent not only a race for the coveted congressional seat, but also a referendum on the future of Democratic politics in Texas and nationally.

The House speaker, Nancy Pelosi, House majority whip, James E Clyburn, and House majority leader, Steny Hoyer, have thrown the full-throated support of the Democratic establishment behind Cuellar, while endorsements from progressive icons such as Bernie Sanders, Elizabeth Warren and Alexandria Ocasio-Cortez have elevated Cisneros as a rising star on the national stage.

If Cuellar wins, this is a story of how the Democratic machine and the old system is still strong in the district. And if Jessica Cisneros wins, the narrative is this is another successful Latina politician carrying the community forward, said Katsuo Nishikawa Chvez, an associate professor of political science at Trinity University.

Cuellar did not grant the Guardians request for an interview.

Cuellar and Cisneros both Mexican American lawyers from Laredo represent two radically different visions of what south Texas is and could be.

Cuellar has served nine terms in the US House of Representatives, where last summer he teamed up with the Republican senator Lindsey Graham to portray migrants as disease carriers and demand that the Biden administration end the surge at the US-Mexico border. By contrast, Cisneros, 28, has spent much of her early career fighting on the frontlines for immigrant families and asylum seekers, and part of her platform is more humane border and immigration policies that include a pathway to citizenship for unauthorized residents.

Their strategies also diverge on campaign finance. Cuellar has funded years of congressional bids with contributions from donors that have notably included the National Rifle Association and oil and gas industry Pacs. Cisneros, meanwhile, has publicly sworn off campaign donations from corporate Pacs and lobbyists and yet still far outpaced Cuellars fundraising numbers during the first quarter of 2022.

At least part of Cisneross fundraising success earlier this year may be linked to the FBIs raid on Cuellars home in January, which immediately embroiled his office in scandal. A Texas Tribune analysis found that in the days after the raid, Cisneross campaign contributions soared, although what exactly the FBI was investigating remains unclear and Cuellar maintains he has done nothing wrong.

Now, in the days leading up to the runoff, another major controversy has taken center stage: the candidates opposing views on reproductive care. After a leaked draft opinion went viral suggesting the supreme courts intention to overturn Roe v Wade the landmark decision that established a constitutional right to abortion in the US Cuellar has faced renewed scrutiny from reproductive rights champions as the lone Democratic representative to vote against codifying the right to an abortion last September.

Cisneros, in turn, has vowed to protect that right. In a statement following the draft leak, she called on the Democratic leadership to withdraw their support of Henry Cuellar who is the last anti-choice Democrat in the House.

The 2022 election is Cisneross second bid to unseat Cuellar, whom she also ran against in 2020 as a first-time, 26-year-old challenger. After she lost that race by less than 4% of the vote, she said she felt compelled to try one more time.

What folks were telling us over and over and over again was that, you know, the way things are right now isnt working, and that they want a different version an alternative version of what south Texas can look like, because they felt like they were being taken for granted, Cisneros said.

Residents in Texas-28 have a lot working against them, which may explain why some could feel like they and their votes are undervalued. For one, increased voter restrictions, closed or relocated polling places, and other serious barriers that require more time and energy make it so that by design, many Texans of color dont vote when they perceive an election to be low stakes.

Everything we see looks to be orchestrated in a way that makes voting for Latinos hard and almost impossible, said Nishikawa Chvez, who suggested it was hard to look at the Texas governments actions and not recognize a systemic interest in suppressing the Latino vote.

In a self-fulfilling prophecy, candidates from both parties also chronically underinvest their limited resources in Latino communities like Texas-28 because they dont know how to reach them and assume they probably wont go to the polls, Nishikawa Chvez said.

Jen Ramos, a state Democratic executive committeewoman for the Texas Democratic party, has been getting out the vote for Cisneros in Laredo and San Antonio, where some residents have told her its the first time their doors have ever been knocked by a political campaign.

The fact that these folks have never had their door knocked on, have never been contacted before, and were talking to people and meeting them where theyre at, thats a real disappointment for an elected official whos been in office for as long as he [Cuellar] has, Ramos said.

If there was anything Ramos noticed growing up in Texas-28, it was the defeated feeling that nothing ever changed within her community, no matter who was in power. Henry Cuellar has been in office almost as long as Ive been alive, and yet nothing has inspired any change or difference, nor has he ever bothered to talk to anybody in the community, she said.

Shes optimistic that things could finally be different with Cisneros representing the district: I think that Jessicas race is the very first time in a long time that the region and the community has seen the sense of hope.

But not everyone in the district agrees with the kind of change Cisneros represents. Texas-28 is a perfect microcosm of how Latino voters are in no way a monolith, and closer to the borders Rio Grande, constituents trend more conservative, Catholic and pro-gun rights than in San Antonios working-class neighborhoods, Nishikawa Chvez explained.

Its a huge district, and its cut in such a way to maximize Republican votes, he said. And so you get a kind of a schizophrenic area.

Generational and gendered divides complicate matters further. Older voters speak Cuellars language around good jobs, border security and Catholic values, while a growing constituency of highly educated young Latinos hear their values represented in Cisneros. Meanwhile, Latina matriarchs are pushing their communities to vote for issues beyond the economy, such as healthcare access, the environment and quality education.

Ultimately, the runoff will come down to who actually turns out, a question that may have a larger impact on how politicians appeal to Latinos in future, Nishikawa Chvez suggested.

How this election goes is going to tell us a little bit about the future, about how to approach or how to campaign and to get the votes of Latino voters in the US, he said.

For now, Cisneros is hoping to find common ground with her neighbors across the district by listening to what they want addressed. When were talking about increasing the minimum wage and Medicare for All, she said, theyre kitchen-table issues that, you know, people are much more concerned about.

Change doesnt happen overnight, Cisneros added. Every little thing that were doing every single day, I mean, is helping us build a brighter future. But I do know that when we win on 24 May, I really hope that it is the beginning of change in south Texas.

Go here to see the original:

Will Texas pick a progressive or anti-abortion Democrat in heated runoff? - The Guardian US

Posted in Democrat | Comments Off on Will Texas pick a progressive or anti-abortion Democrat in heated runoff? – The Guardian US

Wall Street-Funded Democrat PAC to Spend $1 Million in Bid to Unseat Tlaib: Report – Common Dreams

Posted: at 8:18 pm

A new political action committee backed by a major New York hedge fund and Democratic politician turned cable news commentator Bakari Sellers plans to spend more than $1 million in a bid to oust progressive second-term Michigan Democrat Rashida Tlaib from the U.S. House of Representatives in November's midterm elections.

"It's flattering that billionaires who know nothing about our district are so scared of our movement."

Politico reports Urban Empowerment Action PAC announced a new campaign to "elect solutions-oriented Democrats" to Congress.

"UEA PAC's premier race will be in Michigan's 12th Congressional District, where the group plans to spend upwards of $1 million on TV, digital, mail, radio, and print advertising to support Detroit City Clerk Janice Winfrey in her campaign to restore infrastructure, improve educational opportunities in the district, and support the Biden-Harris agenda in D.C.," the new group said in a statement Friday.

Politico does not mention UEA's biggest contributor: According to OpenSecrets.org, the New York-based hedge fund Third Point LLC, founded by multibillionaire investor Daniel S. Loeb, has given $76,355 to the PAC.

Tlaib responded swiftly, tweeting, "Yet another Wall Street billionaire-funded Super PAC running interference in local races, spending millions to peddle lies and distortions, pushing a pro-corporate agenda on a district that has consistently stood against the corporate greed hurting our families."

According to Politico, Sellersthe former South Carolina state lawmaker and failed lieutenant governor candidate who regularly appears on CNN as a political analystis fundraising for UEA PAC. When asked about his endorsement of Winfrey, he told Politico's "The Recast" that "we are hoping that we can have a candidate that doesn't have varying distractions."

Tlaib, who is Palestinian-American, and "Squad" colleague Rep. Ilhan Omar (D-Minn.)the first Muslim-American women elected to Congresshave been smeared as anti-Semites by both Republican and Democratic lawmakers for their advocacy of Palestinian rights, their condemnation of Israeli crimes including apartheid and ethnic cleansing, and their willingness to criticize President Joe Biden over "unconditional" U.S. support for Israel.

Earlier this month, Tlaib introduced a resolution recognizing the Nakbaor "Catastrophe"in which Zionist Jews ethnically cleansed more than 750,000 Palestinian Arabs from their homeland while establishing the nation of Israel.

Sellers, on the other hand, is a staunch supporter of Israel. He also bristles at Tlaib's vote against Biden's bipartisan infrastructure bill, which she rejected after Democratic leadership broke a promise to pass the measure in tandem with the Build Back Better Act. That sweeping climate and social spending package has still not passed, in large part due to obstructionist right-wing members of Tlaib's own party.

Progressives reacted angrily to Politico's reporting.

"Fuck this. We'll make sure Rashida buries them," activist Brett Banditelli tweeted. "She represents all working-class people in her district and in her city."

Strategist Waleed Shahid tweeted: "With Islamophobia on the rise, it is disgraceful to single out the *only* Palestinian member of Congress, who is a civil rights lawyer and represents one of the most Arab-American districts. Shouldn't you focus on holding the Dem majority?"

Read the original post:

Wall Street-Funded Democrat PAC to Spend $1 Million in Bid to Unseat Tlaib: Report - Common Dreams

Posted in Democrat | Comments Off on Wall Street-Funded Democrat PAC to Spend $1 Million in Bid to Unseat Tlaib: Report – Common Dreams

Letter: Which Democrat has best chance to win? – Daily Herald

Posted: at 8:18 pm

Since the end of World War II, the president's party has lost an average of 26 House seats in midterm elections. For Democrats to keep control of the House in the 2022 elections, they will need to successfully hold districts like Illinois' reconfigured 6th Congressional district, which stretches from Villa Park to Tinley Park and is currently rated "lean Democrat" by The Cook Political Report.

In the June 28 primary, 6th District Democratic voters will need to not only consider whether Rep. Sean Casten, the 6th District incumbent, or Rep. Marie Newman, who now serves Illinois' 3rd Congressional District, would best represent them in Congress. They also need to think about who has the best chance of winning the general election.

Casten is the clear choice on both counts. A resident of Downers Grove, Casten proved he could win in contested suburban districts when he defeated six-term Republican incumbent Peter Roskam in 2018 and held off challenger Jeanne Ives in 2020.

Newman, on the other hand, won in the more heavily Democratic 3rd District. While Dan Lipinski had won this district with 73% of the general election vote in 2018, Newman received just 56% of the vote in 2020.

Although Newman has generally voted with the majority of Democrats since joining the House last year, Casten has emerged as a congressional leader in his two terms, particularly on efforts to prevent the worst effects of climate change. He sits on the Select Committee on the Climate Crisis and his work led to funding for clean-energy battery storage and research into low-carbon industrial technologies being included in the Bipartisan Infrastructure Law.

Residents of the 6th district who want Democrats to keep control of the U.S. House should turn out to vote for Sean Casten on June 28.

Allen Hogg

Downers Grove

See the article here:

Letter: Which Democrat has best chance to win? - Daily Herald

Posted in Democrat | Comments Off on Letter: Which Democrat has best chance to win? – Daily Herald

Wisconsin Voters File Lawsuits Against Democrat Cities Over Illegal Drop Box Use In 2020 Election – The Federalist

Posted: at 8:18 pm

Wisconsin voters took legal action against their states five largest cities on Wednesday over the illegal use of unmanned drop boxes during the 2020 election.

Filed by the Thomas More Society on behalf of voters against Green Bay, Kenosha, Madison, Milwaukee, and Racine, the legal complaints allege that city officials ignored state law by implementing unmanned drop boxes over the course of the 2020 cycle.

In 2020, the cities of Milwaukee, Madison, Racine, Kenosha, and Green Bay made an agreement with the nonprofit Center for Tech and Civic Life [CTCL] to use the drop boxes to get these cities residents to vote, said Thomas More Society Special Counsel Erick Kaardal in a press release. This so-calledWisconsin Safe Voting Plan, involved $8.8 million of private grants to these five cities, to target specific populations to vote. It had little, if anything at all to do with keeping voters safe from Covid-19, as it purported to do.

During the 2020 election, CTCL received $400 million from Meta CEO Mark Zuckerberg to finance the infiltration of election offices at the city and county level by left-wing activists and use them as a platform to implement preferred administrative practices, voting methods, and data-sharing agreements, as well as to launch intensive outreach campaigns in areas heavy with Democratic voters, in the words of William Doyle in The Federalist.

According to a report from the Capital Research Center, CTCL distributed a total of 31 grants above the $5,000 minimum to Wisconsin cities and townships, with 28 going directly to specific cities rather than counties.

Out of those 28 grants just 8 of the recipient localities were won by Trump, while 20 were won by Biden, the report reads. Together, these 20 cities received $9 million or 90 percent of all CTCL funds in Wisconsin.

The Capital Research Center findings also reveal that [f]or grants over $5,000, 9 of CTCLs 10 largest per capita grants went to cities which Biden won, with Racine ($21.83), Green Bay ($11.60), Kenosha ($8.63), Milwaukee ($5.91), and Madison ($4.71) receiving the most out of all localities in the state.

The lawsuits from Wisconsin voters come after the Wisconsin Elections Commission refused last month to launch investigations into the five cities for their use of unmanned drop boxes, despite a January ruling from a Waukesha County Circuit Court judge saying that such drop boxes and ballot harvesting violate state law and cannot be used in the upcoming midterm elections.

Its all good and nice, but theres no authority to do it, Judge Michael Bohren said with respect to the use of drop boxes.

Shawn Fleetwood is an intern at The Federalist and a graduate of the University of Mary Washington. He also serves as a state content writer for Convention of States Action and his work has been featured in numerous outlets, including RealClearPolitics, RealClearHealth, and Conservative Review. Follow him on Twitter @ShawnFleetwood

More here:

Wisconsin Voters File Lawsuits Against Democrat Cities Over Illegal Drop Box Use In 2020 Election - The Federalist

Posted in Democrat | Comments Off on Wisconsin Voters File Lawsuits Against Democrat Cities Over Illegal Drop Box Use In 2020 Election – The Federalist